Sort
8,912 grants matching “sars cov 2”
Establishment of a SPF Rhesus Macaque Colony
$2,417,980Deepak Kaushal · Texas Biomedical Research Institute · U42 · FY2023 · OD
Establishment of a SPF Rhesus Macaque Colony
$2,417,980Deepak Kaushal · Texas Biomedical Research Institute · U42 · FY2025 · OD
Establishment of a SPF Rhesus Macaque Colony
$2,417,980Deepak Kaushal · Texas Biomedical Research Institute · U42 · FY2024 · OD
Allergic sensitization through the airway
$2,410,231Donald N Cook · National Institute Of Environmental Health Sciences · ZIA · FY2022 · ES
Vaccine Induced Immunity in the Young and Aged
$2,410,029Rafi Ahmed · Emory University · U19 · FY2020 · AI
Immunological responses to pan-CoV vaccines
$2,408,043Yoshihiro Kawaoka · University Of Wisconsin-Madison · P01 · FY2021 · AI
Clinical Core
$2,406,839Gabriel Alejandro De Erausquin · University Of Texas Hlth Science Center · U19 · FY2025 · AG
Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center
$2,402,774Richard G Wunderink · Northwestern University At Chicago · U19 · FY2024 · AI
An OpenData Portal to share SARS-CoV-2 drug repurposing data in real time
$2,402,379Matthew Hall · National Center For Advancing Translational Sciences · ZIA · FY2023 · TR
Analytical Chemistry
$2,398,371Christopher Arthur Leclair · National Center For Advancing Translational Sciences · ZIC · FY2022 · TR
Tulane National Primate Research Center
$2,396,052Lee Hamm · Tulane University Of Louisiana · P51 · FY2023 · OD
Alzheimer's Disease and Related Dementia-like Sequelae of SARS-CoV-2 Infection: Virus-Host Interactome, Neuropathobiology, and Drug Repurposing
$2,394,473Feixiong Cheng · Cleveland Clinic Lerner Com-Cwru · RF1 · FY2023 · AG
KOMP2-Phase 2 Production and Phenotyping by the DTCC Consortium
$2,391,666Kc Kent Lloyd · University Of California At Davis · UM1 · FY2021 · OD
The Jackson Laboratory Knockout Mouse Production and Phenotyping Project (JAX KOMP2)
$2,391,665Robert E Braun · Jackson Laboratory · UM1 · FY2021 · OD
Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment
$2,391,540Alessandro Sette · La Jolla Institute For Immunology · U19 · FY2022 · AI
Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment
$2,391,540Alessandro Sette · La Jolla Institute For Immunology · U19 · FY2023 · AI
Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment
$2,391,540Alessandro Sette · La Jolla Institute For Immunology · U19 · FY2024 · AI
Mechanisms of Immune Protection Against Respiratory Viruses
$2,380,350Ali Hassan Ellebedy · Washington University · U19 · FY2025 · AI
Mechanisms of Immune Protection Against Respiratory Viruses
$2,380,350Ali Hassan Ellebedy · Washington University · U19 · FY2024 · AI
Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicity
$2,378,661Arjun Deb · University Of California Los Angeles · R01 · FY2023 · DK
COVID-19 Clinical Support and Research
$2,371,299Adrian McDermott · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Task V20: Hamster Sarbecovirus Challenge Model for SARS-CoV-2 Vaccine Testing
$2,365,162Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2024 · AI
Research Project 1: Discovery and dissection of virus-host interactions and pathogenetic mechanisms
$2,360,067Kartik Chandran · Albert Einstein College Of Medicine · U19 · FY2025 · AI
TO MODIFY THE CONTRACT AND ADD ADDITIONAL FUNDING TO CONFIGURE A SMARTPHONE AND WEB-BASED DIGITAL HEALTH SOLUTION TO SUPPORT THE GENERAL PUBLIC USE OF
$2,358,083Vik Kheterpal · Careevolution, Inc. · N02 · FY2022 · HL
Therapeutics for Inpatients with COVID-19 (TICO) Trial
$2,357,228Laura McNay · National Institute Of Allergy And Infectious Diseases · Y01 · FY2021 · AI